Ophthalmic manifestations of giant cell arteritis

References

• Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11. doi: 10.1002/art.37715
   PubMed Web of Science ®Google Scholar
• Ma-Krupa W, Jeon MS, Spoerl S, et al. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med. 2004;199(2):173–183. doi: 10.1084/jem.20030850
   PubMed Web of Science ®Google Scholar
• Weyand CM, Schönberger J, Oppitz U, et al. Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes. J Exp Med. 1994;179(3):951–960. doi: 10.1084/jem.179.3.951
   PubMed Web of Science ®Google Scholar
• Nordborg C, Nordborg E, Petursdottir V. Giant cell arteritis. Epidemiology, etiology and pathogenesis. APMIS Acta Pathol Microbiol Immunol Scand. 2000;108(11):713–724. doi: 10.1034/j.1600-0463.2000.d01-19.x
   PubMed Web of Science ®Google Scholar
• Piggott K, Biousse V, Newman NJ, et al. Vascular damage in giant cell arteritis. Autoimmunity. 2009;42(7):596–604. doi: 10.1080/08916930903002495
   PubMed Web of Science ®Google Scholar
• Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014;371(17):1653. doi: 10.1056/NEJMcp1214825
   PubMedGoogle Scholar
• Salvarani C, Crowson CS, O’Fallon WM, et al. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Rheum. 2004;51(2):264–268. doi: 10.1002/art.20227
   PubMed Web of Science ®Google Scholar
• Weyand CM, Hicok KC, Hunder GG, et al. The HLA-DRB1 locus as a genetic component in giant cell arteritis. Mapping of a disease-linked sequence motif to the antigen binding site of the HLA-DR molecule. J Clin Invest. 1992;90(6):2355–2361. doi: 10.1172/JCI116125
   PubMed Web of Science ®Google Scholar
• Dagostin MA, Pereira RMR. Giant cell arteritis: current advances in pathogenesis and treatment. Vascular Biology - Selection Of Mechanisms And Clinical Applications. INTECHOPEN. 637406496000000000. doi: 10.5772/intechopen.91018
   Google Scholar
• Li KJ, Semenov D, Turk M, et al. A meta-analysis of the epidemiology of giant cell arteritis across time and space. Arthritis Res Ther. 2021;23(1):82. doi: 10.1186/s13075-021-02450-w
   PubMed Web of Science ®Google Scholar
• Sharma A, Mohammad AJ, Turesson C. Incidence and prevalence of giant cell arteritis and polymyalgia rheumatica: a systematic literature review. Semin Arthritis Rheum. 2020;50(5):1040–1048. doi: 10.1016/j.semarthrit.2020.07.005
   PubMed Web of Science ®Google Scholar
• Garvey TD, Koster MJ, Crowson CS, et al. Incidence, survival, and diagnostic trends in GCA across seven decades in a North American population-based cohort. Semin Arthritis Rheum. 2021;51(6):1193–1199. doi: 10.1016/j.semarthrit.2021.09.006
   PubMed Web of Science ®Google Scholar
• Hu Z, Yang Q, Zeng S, et al. Giant cell arteritis in China: a prospective investigation. Angiology. 2002;53(4):457–463. doi: 10.1177/000331970205300413
   PubMed Web of Science ®Google Scholar
• Cheng CK, Lee CC, Huang KH, et al. Giant cell (Temporal) arteritis with anterior ischemic optic neuropathy: a biopsy-proven case in Taiwan. J Formos Med Assoc Taiwan Yi Zhi. 2010;109(7):550–554. doi: 10.1016/S0929-6646(10)60090-3
   PubMed Web of Science ®Google Scholar
• Yoon HJ, Park SW, Lee HK, et al. Bilateral arteritic anterior ischemic optic neuropathy associated with giant cell arteritis in Korea. Korean J Ophthalmol KJO. 2017;31(5):466–467. doi: 10.3341/kjo.2017.0089
   PubMedGoogle Scholar
• Kobayashi S, Yano T, Matsumoto Y, et al. Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide survey. Arthritis Rheum. 2003;49(4):594–598. doi: 10.1002/art.11195
   PubMedGoogle Scholar
• Hayreh SS. Giant cell arteritis: its ophthalmic manifestations. Indian J Ophthalmol. 2021;69(2):227–235. doi: 10.4103/ijo.IJO_1681_20
   PubMed Web of Science ®Google Scholar
• Albarrak AM, Mohammad Y, Hussain S, et al. Simultaneous bilateral posterior ischemic optic neuropathy secondary to giant cell arteritis: a case presentation and review of the literature. BMC Ophthalmol. 2018;18(1):317. doi: 10.1186/s12886-018-0994-9
   PubMedGoogle Scholar
• Fainaru M, Friedman G, Friedman B. Temporal arteritis in Israel. A review of 47 patients. J Rheumatol. 1979;6(3):330–335.
   PubMed Web of Science ®Google Scholar
• Mader TH, Werner RP, Chamberlain DG, et al. Giant cell arteritis in Alaska natives. Can J Ophthalmol J Can Ophtalmol. 2009;44(1):53–56. doi: 10.3129/i08-164
   PubMed Web of Science ®Google Scholar
• Alba MA, Mena-Madrazo JA, Reyes E, et al. Giant cell arteritis in Mexican patients. JCR: J Clin Rheumatol. 2012;18(1):1. doi: 10.1097/RHU.0b013e31823e2e35
   PubMed Web of Science ®Google Scholar
• Larsson K, Mellström D, Nordborg E, et al. Early menopause, low body mass index, and smoking are independent risk factors for developing giant cell arteritis. Ann Rheum Dis. 2006;65(4):529–532. doi: 10.1136/ard.2005.039404
   PubMed Web of Science ®Google Scholar
• Narváez J, Bernad B, Díaz Torné C, et al. Low serum levels of DHEAS in untreated polymyalgia rheumatica/giant cell arteritis. J Rheumatol. 2006;33(7):1293–1298.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ, et al. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore). 2005;84(5):269–276. doi: 10.1097/01.md.0000180042.42156.d1
   PubMed Web of Science ®Google Scholar
• Gran JT, Myklebust G, Wilsgaard T, et al. Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls. Rheumatol Oxf Engl. 2001;40(11):1238–1242. doi: 10.1093/rheumatology/40.11.1238
   PubMed Web of Science ®Google Scholar
• González-Gay MA, García-Porrúa C, Vázquez-Caruncho M, et al. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J Rheumatol. 1999;26(6):1326–1332.
   PubMed Web of Science ®Google Scholar
• McKillop E, Tejwani D, Weir C, et al. Anterior segment ischaemia with giant cell arteritis. Can J Ophthalmol J Can Ophtalmol. 2006;41(2):201–203. doi: 10.1139/I06-009
   PubMed Web of Science ®Google Scholar
• Calcagni A, Claes CA, Maheshwari M, et al. Hypotony as a presentation of giant cell arteritis. Eye Lond Engl. 2007;21(1):123–124. doi: 10.1038/sj.eye.6702436
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol. 1998;125(4):509–520. doi: 10.1016/s0002-9394(99)80192-5
   PubMed Web of Science ®Google Scholar
• Alsolaimani RS, Bhavsar SV, Khalidi NA, et al. Severe intracranial involvement in giant cell arteritis: 5 cases and literature review. J Rheumatol. 2016;43(3):648–656. doi: 10.3899/jrheum.150143
   PubMed Web of Science ®Google Scholar
• Adams HP. Cerebral vasculitis. Handb Clin Neurol. 2014;119:475–494. doi: 10.1016/B978-0-7020-4086-3.00031-X
   PubMedGoogle Scholar
• Reddi S, Vollbracht S. Giant cell arteritis associated with orbital pseudotumor. Headache. 2013;53(9):1488–1489. doi: 10.1111/head.12100
   PubMed Web of Science ®Google Scholar
• de Heide LJ, Talsma MA. Giant-cell arteritis presenting as an orbital pseudotumor. Neth J Med. 1999;55(4):196–198. doi: 10.1016/s0300-2977(99)00078-9
   PubMed Web of Science ®Google Scholar
• Borruat FX, Bogousslavsky J, Uffer S, et al. Orbital infarction syndrome. Ophthalmol. 1993;100(4):562–568. doi: 10.1016/s0161-6420(93)31606-4
   PubMed Web of Science ®Google Scholar
• Kim DD, Budhram A, Pelz D, et al. Teaching NeuroImages: Orbital infarction syndrome from giant cell arteritis. Neurology. 2016;87(22):e269. doi: 10.1212/WNL.0000000000003381
   PubMed Web of Science ®Google Scholar
• Fernandez S, Adhiyaman V. Giant cell arteritis presenting as peri-orbital ecchymosis. Age Ageing. 2005;34(1):85–86. doi: 10.1093/ageing/afh227
   PubMed Web of Science ®Google Scholar
• Saravanan V, Pugmire S, Smith M, et al. Patient-reported involvement of the eighth cranial nerve in giant cell arteritis. Clin Rheumatol. 2019;38(12):3655–3660. doi: 10.1007/s10067-019-04747-3
   PubMed Web of Science ®Google Scholar
• Ross M, Bursztyn L, Superstein R, et al. Multiple Cranial Nerve Palsies in Giant Cell Arteritis. J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc. 2017;37(4):398–400. doi: 10.1097/WNO.0000000000000529
   PubMed Web of Science ®Google Scholar
• Cherng Chan G. Unilateral partial cranial nerve palsy in a case of giant cell arteritis. Aust J Gen Pract. 2021;50(8):561–563. doi: 10.31128/AJGP-11-20-5713
   PubMed Web of Science ®Google Scholar
• Ciofalo A, Gulotta G, Iannella G, et al. Giant cell arteritis (GCA): pathogenesis, clinical aspects and treatment approaches. Curr Rheumatol Rev. 2019;15(4):259–268. doi: 10.2174/1573397115666190227194014
   PubMed Web of Science ®Google Scholar
• Knockaert DC, Vanneste LJ, Bobbaers HJ. Fever of unknown origin in elderly patients. J Am Geriatr Soc. 1993;41(11):1187–1192. doi: 10.1111/j.1532-5415.1993.tb07301.x
   PubMed Web of Science ®Google Scholar
• Glutz von Blotzheim S, Borruat FX. Neuro-ophthalmic complications of biopsy-proven giant cell arteritis. Eur J Ophthalmol. 1997;7(4):375–382. doi: 10.1177/112067219700700412
   PubMedGoogle Scholar
• Mairot K, Sené T, Lecler A, et al. Paracentral acute middle maculopathy in giant cell arteritis. Retina (Philadelphia, Pa). 2022;42(3):476–484. doi: 10.1097/IAE.0000000000003339
   PubMed Web of Science ®Google Scholar
• Casella AMB, Mansour AM, EC S, et al. Choroidal ischemia as one cardinal sign in giant cell arteritis. Int J Retina Vitreous. 2022;8(1):69. doi: 10.1186/s40942-022-00422-z
   PubMedGoogle Scholar
• Dejaco C, Ramiro S, Bond M, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. Ann Rheum Dis. 2023 Aug 7. doi: 10.1136/ard-2023-224543
   Google Scholar
• He J, Williamson L, Ng B, et al. The diagnostic accuracy of temporal artery ultrasound and temporal artery biopsy in giant cell arteritis: a single center Australian experience over 10 years. Int J Of Rheum Dis. 2022;25(4):447–453. doi: 10.1111/1756-185X.14288
   PubMed Web of Science ®Google Scholar
• Stone JH, Tuckwell K, Dimonaco S, et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med. 2017;377(4):317–328. doi: 10.1056/NEJMoa1613849
   PubMed Web of Science ®Google Scholar
• Unizony SH, Dasgupta B, Fisheleva E, et al. Design of the tocilizumab in giant cell arteritis trial. Int J Rheumatol. 2013;2013:912562. doi: 10.1155/2013/912562
   PubMedGoogle Scholar
• Ashton-Key MR, Gallagher PJ. False-negative temporal artery biopsy. Am J Surg Pathol. 1992;16(6):634–635. doi: 10.1097/00000478-199206000-00014
   PubMed Web of Science ®Google Scholar
• Duhaut P, Pinède L, Bornet H, et al. Biopsy proven and biopsy negative temporal arteritis: differences in clinical spectrum at the onset of the disease. Groupe de recherche sur l’Artérite à cellules géantes. Ann Rheum Dis. 1999;58(6):335–341. doi: 10.1136/ard.58.6.335
   PubMed Web of Science ®Google Scholar
• Calvo Romero JM. Giant cell arteritis. An Med Interna Madr Spain 1984. 2002;19(5):257–262. doi: 10.4321/S0212-71992002000500011
   Google Scholar
• Kermani TA, Schmidt J, Crowson CS, et al. Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum. 2012;41(6):866–871. doi: 10.1016/j.semarthrit.2011.10.005
   PubMed Web of Science ®Google Scholar
• Ellis ME, Ralston S. The ESR in the diagnosis and management of the polymyalgia rheumatica/giant cell arteritis syndrome. Ann Rheum Dis. 1983;42(2):168–170. doi: 10.1136/ard.42.2.168
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Podhajsky PA, Raman R, et al. Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol. 1997;123(3):285–296. doi: 10.1016/S0002-9394(14)70123-0
   PubMed Web of Science ®Google Scholar
• Kyle V, Cawston TE, Hazleman BL. Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up. Ann Rheum Dis. 1989;48(8):667–671. doi: 10.1136/ard.48.8.667
   PubMed Web of Science ®Google Scholar
• Smetana GW, Shmerling RH. Does this patient have temporal arteritis? JAMA. 2002;287(1):92–101. doi: 10.1001/jama.287.1.92
   PubMed Web of Science ®Google Scholar
• Huston KA. Temporal arteritis: a 25-year epidemiologic, clinical, and pathologic study. Ann Intern Med. 1978;88(2):162–167. doi: 10.7326/0003-4819-88-2-162
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Zimmerman B. Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies. Ophthalmol J Int Ophtalmol Int J Ophthalmol Z Augenheilkd. 2003;217(4):239–259. doi: 10.1159/000070631
   Google Scholar
• Villiger PM, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Lond Engl. 2016;387(10031):1921–1927. doi: 10.1016/S0140-6736(16)00560-2
   PubMed Web of Science ®Google Scholar
• Hellmich B, Agueda A, Monti S, et al. 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79(1):19–30.
   PubMed Web of Science ®Google Scholar
• Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;56(8):2789–2797. doi: 10.1002/art.22754
   PubMed Web of Science ®Google Scholar
• Schönau V, Roth J, Tascilar K, et al. Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study. Rheumatol Oxf Engl. 2021;60(8):3851–3861. doi: 10.1093/rheumatology/keab332
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Biousse V. Treatment of acute visual loss in giant cell arteritis: should we prescribe high-dose intravenous steroids or just oral steroids? J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc. 2012;32(3):278–287. doi: 10.1097/WNO.0b013e3182688218
   PubMed Web of Science ®Google Scholar
• Singh AG, Kermani TA, Crowson CS, et al. Visual manifestations in giant cell arteritis: trend over 5 decades in a population-based cohort. J Rheumatol. 2015;42(2):309–315. doi: 10.3899/jrheum.140188
   PubMed Web of Science ®Google Scholar
• Danesh-Meyer H, Savino PJ, Gamble GG. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmol. 2005;112(6):1098–1103. doi: 10.1016/j.ophtha.2005.01.036
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand. 2002;80(4):355–367. doi: 10.1034/j.1600-0420.2002.800403.x
   PubMedGoogle Scholar
• Aiello PD, Trautmann JC, McPhee TJ, et al. Visual prognosis in giant cell arteritis. Ophthalmol. 1993;100(4):550–555. doi: 10.1016/s0161-6420(93)31608-8
   PubMed Web of Science ®Google Scholar
• Hayreh SS, Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmol. 2003;110(6):1204–1215. doi: 10.1016/S0161-6420(03)00228-8
   PubMed Web of Science ®Google Scholar
• González-Gay MA, Blanco R, Rodríguez-Valverde V, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 1998;41(8):1497–1504.
   PubMed Web of Science ®Google Scholar
• Foroozan R, Deramo VA, Buono LM, et al. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmol. 2003;110(3):539–542. doi: 10.1016/S0161-6420(02)01775-X
   PubMed Web of Science ®Google Scholar
• Chan CC, Paine M, O’Day J. Steroid management in giant cell arteritis. Br J Ophthalmol. 2001;85(9):1061–1064. doi: 10.1136/bjo.85.9.1061
   PubMed Web of Science ®Google Scholar
• Liu GT, Glaser JS, Schatz NJ, et al. Visual morbidity in giant cell arteritis. Clinical characteristics and prognosis for vision. Ophthalmol. 1994;101(11):1779–1785. doi: 10.1016/s0161-6420(94)31102-x
   PubMed Web of Science ®Google Scholar
• Kermani TA, Warrington KJ, Cuthbertson D, et al. Disease relapses among patients with giant cell arteritis: a prospective, longitudinal cohort study. J Rheumatol. 2015;42(7):1213–1217. doi: 10.3899/jrheum.141347
   PubMed Web of Science ®Google Scholar
• Labarca C, Koster MJ, Crowson CS, et al. Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. Rheumatol Oxf Engl. 2016;55(2):347–356. doi: 10.1093/rheumatology/kev348
   PubMed Web of Science ®Google Scholar
• Martinez-Lado L, Calviño-Díaz C, Piñeiro A, et al. Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine (Baltimore). 2011;90(3):186–193. doi: 10.1097/MD.0b013e31821c4fad
   PubMed Web of Science ®Google Scholar
• Alba MA, García-Martínez A, Prieto-González S, et al. Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine (Baltimore). 2014;93(5):194–201. doi: 10.1097/MD.0000000000000033
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet Lond Engl. 2008;372(9634):234–245. doi: 10.1016/S0140-6736(08)61077-6
   PubMed Web of Science ®Google Scholar
• Hoffman GS. Giant cell arteritis. Ann Intern Med. 2016;165(9):ITC65–ITC80. doi: 10.7326/AITC201611010
   PubMed Web of Science ®Google Scholar
• Keser G, Atagunduz P, Soy M. Recent advances in the diagnosis and therapy of large vessel vasculitis. Pol Arch Intern Med. 2022;132(6):16272. doi: 10.20452/pamw.16272
   PubMedGoogle Scholar
• Schmidt WA, Dasgupta B, Sloane J, et al. A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis. Arthritis Res Ther. 2023;25(1):199. doi: 10.1186/s13075-023-03177-6
   PubMed Web of Science ®Google Scholar
• Cid MC, Unizony SH, Blockmans D, et al. Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81(5):653. doi: 10.1136/annrheumdis-2021-221865
   PubMed Web of Science ®Google Scholar
• Conway R, O’Neill L, O’Flynn E, et al. Ustekinumab for the treatment of refractory giant cell arteritis. Ann Rheum Dis. 2016;75(8):1578–1579. doi: 10.1136/annrheumdis-2016-209351
   PubMed Web of Science ®Google Scholar
• Matza MA, Fernandes AD, Stone JH, et al. Ustekinumab for the treatment of giant cell arteritis. Arthritis Care Res. 2021;73(6):893–897. doi: 10.1002/acr.24200
   Web of Science ®Google Scholar
• Venhoff N, Schmidt WA, Bergner R, et al. Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Rheumatol. 2023;5(6):e341–e350. doi: 10.1016/S2665-9913(23)00101-7
   PubMedGoogle Scholar
• Cid MC, Unizony S, Pupim L, et al. Op0059 mavrilimumab (anti gm-csf receptor a monoclonal antibody) reduces risk of flare and increases sustained remission in a phase 2 trial of patients with giant cell arteritis. Ann Rheum Dis. 2021;80(Suppl 1):31–32.
   PubMedGoogle Scholar
• Sandovici M, van der Geest KSM, van Sleen Y, et al. Need and value of targeted immunosuppressive therapy in giant cell arteritis. RMD Open. 2022;8(1):e001652. doi: 10.1136/rmdopen-2021-001652
   PubMed Web of Science ®Google Scholar
• Castañeda S, Prieto-Peña D, Vicente-Rabaneda EF, et al. Advances in the treatment of giant cell arteritis. J Clin Med. 2022;11(6):1588. doi: 10.3390/jcm11061588
   PubMed Web of Science ®Google Scholar
• Langford CA, Cuthbertson D, Ytterberg SR, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol Hoboken NJ. 2017;69(4):837–845. doi: 10.1002/art.40044
   PubMed Web of Science ®Google Scholar
• Janssen Research & Development, LLC. A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-Of-Concept Study To Evaluate Guselkumab For The Treatment Of Participants With New-Onset Or Relapsing Giant Cell Arteritis. clinicaltrials.gov; 2023 [Cited 2022 Dec 31]. Available from: https://clinicaltrials.gov/study/NCT04633447
   Google Scholar
• Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146(9):621–630. doi: 10.7326/0003-4819-146-9-200705010-00004
   PubMed Web of Science ®Google Scholar
• Seror R, Baron G, Hachulla E, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis. 2014;73(12):2074–2081. doi: 10.1136/annrheumdis-2013-203586
   PubMed Web of Science ®Google Scholar
• Martínez-Taboada VM, Rodríguez-Valverde V, Carreño L, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis. 2008;67(5):625–630.
   PubMed Web of Science ®Google Scholar
• Kamal S, Al Othman B, Kini A, et al. Infectious keratitis as the presenting sign of giant cell arteritis. Can J Ophthalmol J Can Ophtalmol. 2020;55(5):e182–e185.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Morgan ML, Almarzouqi SJ, et al. Apical Orbital Aspergillosis Complicating Giant Cell Arteritis. J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc. 2016;36(2):159–163. doi: 10.1097/WNO.0000000000000344
   PubMed Web of Science ®Google Scholar
• Hussain M, Kini A, Al Othman B, et al. Arteritic orbital ischemia producing afferent and efferent pupillary defects. J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc. 2020;40(4):530–532. doi: 10.1097/WNO.0000000000000838
   PubMed Web of Science ®Google Scholar
• Pellegrini F, Brocca D, Calandriello L, et al. Comment to: “Ahuja as et al: paracentral acute middle maculopathy as a manifestation of giant cell arteritis”. Journal Of Neuro-Ophthalmology. 2022 Feb 28;42(2):e533–e533.
   PubMed Web of Science ®Google Scholar
• Hubbard D, Harish Bindiganavile S, Divatia M, et al. Dry nonproductive cough as the presenting symptom of giant cell arteritis. J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc. 2021;41(4):e746–e748. doi: 10.1097/WNO.0000000000001166
   PubMed Web of Science ®Google Scholar
• Somani AN, Al Othman B, Kini T, et al. Bilateral scalp necrosis in giant cell arteritis. J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc. 2021;41(1):e125–e127. doi: 10.1097/WNO.0000000000000862
   PubMed Web of Science ®Google Scholar
• Wang Q, Mortensen P, Lee AG. Neuro-ophthalmic manifestations of giant cell arteritis-myelodysplastic subtype. J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc. 2023 Jan 4. doi: 10.1097/WNO.0000000000001767
   Google Scholar
• Nawash BS, Ong J, Mortensen P, et al. Giant cell arteritis presenting with pulseless disease. J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc. 2023 Jun 14; Publish Ahead of Print. doi: 10.1097/WNO.0000000000001876
   Google Scholar
• Le N, Vickers A, Prospero Ponce C, et al. Vestibulocochlear symptoms as the initial presentation of giant cell arteritis. Can J Ophthalmol J Can Ophtalmol. 2019;54(1):e1–e3. doi: 10.1016/j.jcjo.2018.04.006
   PubMed Web of Science ®Google Scholar
• Jensen GL, Al Othman B, Kini A, et al. Internuclear Ophthalmoplegia as the presenting sign of giant cell arteritis. J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc. 2020;40(1):92–94. doi: 10.1097/WNO.0000000000000843
   PubMed Web of Science ®Google Scholar
• Ling JD, Hashemi N, Lee AG. Throat pain as a presenting symptom of giant cell arteritis. J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc. 2012;32(4):384. doi: 10.1097/WNO.0b013e318270ffaf
   PubMed Web of Science ®Google Scholar
• Rezaei S, Prospero Ponce CM, Vickers A, et al. Giant cell arteritis relapse presenting as idiopathic orbital inflammation. Can J Ophthalmol J Can Ophtalmol. 2020;55(1):e36–e39. doi: 10.1016/j.jcjo.2019.05.005
   PubMed Web of Science ®Google Scholar
• Amin SD, Vickers A, Hong BY, et al. Chronic myelomonocytic leukemia-related vasculitis mimicking giant cell arteritis. Can J Ophthalmol J Can Ophtalmol. 2019;54(3):e140–e145.
   PubMed Web of Science ®Google Scholar
• Duong AA, Bhat N, Bindiganavile SH, et al. Calciphylaxis a giant cell arteritis mimic: a case report and review of the literature. J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc. 2022;42(1):e362–e366. doi: 10.1097/WNO.0000000000001395
   PubMed Web of Science ®Google Scholar
• Sadun A, Gordon L. Should tocilizumab be used routinely in new patients with a diagnosis of giant cell arteritis? J Neuroophthalmol. 2020;40(1):117. doi: 10.1097/WNO.0000000000000869
   PubMed Web of Science ®Google Scholar
• Pashaei-Marandi A, Kini TA, Al Othman B, et al. The “bone dry” temporal artery biopsy surgical field in giant cell arteritis. Ophthalmic Plast Reconstr Surg. 2020;36(1):e26. doi: 10.1097/IOP.0000000000001409
   PubMed Web of Science ®Google Scholar
• Luqmani R, Lee E, Singh S, et al. The role of ultrasound compared to biopsy of temporal arteries in the diagnosis and treatment of giant cell arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. Health Technol Assess Winch Engl. 2016;20(90):1–238. doi: 10.3310/hta20900
   PubMed Web of Science ®Google Scholar
• Karassa FB, Matsagas MI, Schmidt WA, et al. Meta-analysis: test performance of ultrasonography for giant-cell arteritis. Ann Intern Med. 2005;142(5):359–369. doi: 10.7326/0003-4819-142-5-200503010-00011
   PubMed Web of Science ®Google Scholar
• Noumegni SR, Hoffmann C, Cornec D, et al. Temporal Artery Ultrasound to Diagnose Giant Cell Arteritis: A Practical Guide. Ultrasound Med Biol. 2021;47(2):201–213. doi: 10.1016/j.ultrasmedbio.2020.10.004
   PubMed Web of Science ®Google Scholar
• Chrysidis S, Døhn UM, Terslev L, et al. Diagnostic accuracy of vascular ultrasound in patients with suspected giant cell arteritis (EUREKA): a prospective, multicentre, non-interventional, cohort study. Lancet Rheumatol. 2021;3(12):e865–e873. doi: 10.1016/S2665-9913(21)00246-0
   PubMedGoogle Scholar
• Ponte C, Grayson PC, Robson JC, et al. 2022 American college of rheumatology/EULAR classification criteria for giant cell arteritis. Ann Rheum Dis. 2022;81(12):1647–1653.
   PubMed Web of Science ®Google Scholar
• Narváez J, Estrada P, Vidal-Montal P, et al. Performance of the new 2022 ACR/EULAR classification criteria for giant cell arteritis in clinical practice in relation to its clinical phenotypes. Autoimmun Rev. 2023;22(10):103413. doi: 10.1016/j.autrev.2023.103413
   PubMed Web of Science ®Google Scholar
• van der Geest KSM, Borg F, Kayani A, et al. Novel ultrasonographic halo score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia. Ann Rheum Dis. 2020;79(3):393–399.
   PubMed Web of Science ®Google Scholar
• Panneerselvam S, Raviskanthan S, Mortensen PW, et al. Giant cell arteritis presenting as central retinal artery occlusion and Optic Perineuritis: the importance of contrast MRI of the orbit. Journal Of Neuro-Ophthalmology. 2021 Dec 16;43(4):e105–e106.
   PubMed Web of Science ®Google Scholar
• Nguyen KK, Al Othman BA, Kini AT, et al. Perineural optic nerve enhancement in giant cell arteritis: a case report and review of the literature. J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc. 2021;41(1):e42–e45. doi: 10.1097/WNO.0000000000000914
   PubMed Web of Science ®Google Scholar
• Tseng AM, Harish Bindiganavile S, Bhat N, et al. Optic PErineuritis distinguishing arteritic ischaemic from amiodarone-associated optic neuropathy. Neuro-Ophthalmol Aeolus Press. 2021;45(5):329–333. doi: 10.1080/01658107.2020.1819342
   PubMed Web of Science ®Google Scholar
• Duftner C, Dejaco C, Sepriano A, et al. Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systematic literature review and meta-analysis informing the EULAR recommendations. RMD Open. 2018;4(1):e000612. doi: 10.1136/rmdopen-2017-000612
   PubMed Web of Science ®Google Scholar
• Monti S, Bartoletti A, Bellis E, et al. Fast-track ultrasound clinic for the diagnosis of giant cell arteritis changes the prognosis of the disease but not the risk of future relapse. Front Med. 2020;7:589794. doi: 10.3389/fmed.2020.589794
   PubMed Web of Science ®Google Scholar
• Lyons HS, Quick V, Sinclair AJ, et al. A new era for giant cell arteritis. Eye. 2020;34(6):1013–1026. doi: 10.1038/s41433-019-0608-7
   PubMed Web of Science ®Google Scholar
• Sebastian A, Tomelleri A, Kayani A, et al. Probability-based algorithm using ultrasound and additional tests for suspected GCA in a fast-track clinic. RMD Open. 2020;6(3):e001297. doi: 10.1136/rmdopen-2020-001297
   PubMed Web of Science ®Google Scholar
• Almarzouqi SJ, Morgan ML, Lee AG. Treatment of giant cell arteritis. Curr Opin Ophthalmol. 2015;26(6):469–475. doi: 10.1097/ICU.0000000000000201
   PubMed Web of Science ®Google Scholar
• Kanakamedala A, Hussain M, Kini A, et al. Corticosteroid Usage in Giant Cell Arteritis. Neuro-Ophthalmol Aeolus Press. 2021;45(1):17–22. doi: 10.1080/01658107.2020.1767656
   PubMed Web of Science ®Google Scholar
• Jogimahanti AV, Kini AT, Irwin LE, et al. The COst-effectiveness of tocilizumab (Actemra) therapy in giant cell arteritis. J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc. 2021;41(3):342–350. doi: 10.1097/WNO.0000000000001220
   PubMed Web of Science ®Google Scholar